Sun Pharmaceutical Industries
Biosimilar developer, India. 2 development products across 2 molecules: ranibizumab, teriparatide.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Ranibizumab | Sun Pharma ranibizumab | · | · | · | · | · | Mar 2023 | · | 1/7 |
| Teriparatide | Teriparatide Sun | · | · | MHRA | · | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
Companies on the same molecules
Developers whose portfolios overlap most with Sun Pharmaceutical Industries, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- CDSCOMar 2023Sun Pharmaceutical Industries (INN only), ranibizumab
Compare Sun Pharmaceutical Industries with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant